This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Pharmaceutical Firm, ARTEC, Inc., Reports Moving On In The Development Of An Improved Tubercin™ And The Testing Of HIV/AIDS Human Patients In Africa

ARTEC, Inc., (Pink Sheets: ATKJ), has improved Tubercin T-5 an immunostimulant. In the last two years, Artec asserts that Tubercin™ has improved significantly and tested in Africa, in the company’s opinion, with positive results on human patients afflicted with HIV/AIDS. Under strict confidential conditions, the results received were most encouraging. Artec is engaged in full pursuit of obtaining FDA registration of Tubercin™ in Africa.

With ample funding, the success of Artec is within reach. The steady support of Artec’s shareholders and associates has fostered its accomplishments. Artec thanks all the aforementioned for their loyalty and support.

Artec Inc. is a small entrepreneurial pharmaceutical company in a very competitive field of "Discovering Medicine" to curb HIV/AIDS and cancer. The costs involved are very steep and the challenges bordering on insurmountable. Artec has succeeded in coming this far where, in the company’s opinion, significant research for many years and billions of dollars spent have not. Artec thanks its partner Dr. Tai Ho Chung, his son C.C. Chung and Kyungpook National University (Seoul, Korea) for the patented baseline research prototype, Tubercin™. T-5. Artec looks forward to working together with Dr. Chung and C.C. Chung to bring this improved Tubercin to the world. Artec’s Leading Scientist, Dr. J.K. Park and his associates have also helped, in the company’s view, improve the efficacy of the new Tubercin. Artec also thanks Dr. J.K. Park and everyone working under his leadership and in unison with his association with them.

Artec is serious about the future. The firm has recently explored such issues as Permanent Headquarters; High Volume Manufacturing of Tubercin; and Developing a Vaccine for Prevention of HIV/AIDS yet Impacting HIV/AIDS and cancer. Artec’s progress in the next few months is considered critical for continued successes.

Artec is resolved to bring Tubercin to the market in the near future. Artec appreciates the continued support. The company will disclose more appropriate and specific information in the future. The confidential agreements do not afford Artec the liberty to disclose specific information at this time.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs